arrow
T

Toshio Takagi

Tokyo Women's Medical University
H指数:34
被引数:6,619

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Comparison of clinical outcomes of cabozantinib plus nivolumab and lenvatinib plus pembrolizumab in patients with metastatic renal cell carcinoma

比较卡博替尼联合纳武利尤单抗与伦伐替尼联合帕博利珠单抗在转移性肾细胞癌患者中的临床结局

2026-01-010
OA
Risk Assessment of Cytomegalovirus Reactivation After Kidney Transplantation Under a Universal Preemptive Strategy in the Era of Intravenous Immunoglobulin-Based Desensitization Therapy

肾移植后巨细胞病毒复发的风险评估:在静脉免疫球蛋白为基础的致敏治疗时代下采用普遍抢先策略

2026-01-011
PRE
Comparison of real-world outcomes between nivolumab plus ipilimumab and lenvatinib plus pembrolizumab or nivolumab plus cabozantinib combination therapies for previously untreated advanced renal cell carcinoma

比较纳武利尤单抗联合伊匹木单抗与乐伐替尼联合帕博利珠单抗或纳武利尤单抗联合卡博替尼联合疗法在既往未治疗的晚期肾细胞癌中的真实世界结局

2025-09-012
PRE
Impact of starting dose of tyrosine kinase inhibitors on outcomes following combination therapy of immune checkpoint inhibitors with tyrosine kinase inhibitors for previously untreated advanced renal cell carcinoma

起始剂量酪氨酸激酶抑制剂对免疫检查点抑制剂联合酪氨酸激酶抑制剂治疗初治晚期肾细胞癌后结局的影响

2025-09-010
PRE
Case Report: complete response to preoperative ipilimumab and nivolumab combination therapy in advanced papillary renal cell carcinoma with inferior vena cava tumor thrombus and multiple metastases

病例报告:接受术前伊匹木单抗和纳武利尤单抗联合治疗取得完全缓解的进展期乳头状肾细胞癌,伴有下腔静脉瘤栓和多发转移。

2025-08-260
OA
Sex differences in immunotherapy outcomes and tumor-infiltrating immune cell profiles in patients with advanced renal cell carcinoma

免疫疗法结局和肿瘤浸润免疫细胞表型在晚期肾细胞癌患者中的性别差异

2025-01-030
OA
Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the CLEAR trial

lenvatinib联合pembrolizumab与舒尼替尼治疗的肾细胞癌患者基线转移的临床结果: CLEAR试验的事后分析

2024-12-300
OA